Braingrade

Braingrade sits at the intersection of neuroscience, medical devices, and neurotechnology. Its stated product, the Intelligent Brain Implant (DBS/BCI), combines deep brain stimulation with a brain-computer interface and is aimed specifically at preserving brain health and enhancing cognition in Alzheimer’s patients. The broader fields of neuromodulation, implantable medical devices, and brain-computer interfaces are relevant areas of competition, but no specific peer should be attributed to Braingrade without stronger evidence. The company is privately held and its only recorded financing is a $1 million pre-seed round dated Oct 1, 2021, placing the disclosed funding profile at an early stage. Its described team combines neurotechnology executives with memory researchers, neurosurgeons, and neurologists. That multidisciplinary composition and Alzheimer’s focus are the clearest differentiators in the current profile; details on technical validation, intellectual-property status, clinical partners, and market adoption remain limited.

Braingrade’s disclosed trajectory is defined by an early founding period, a patent-related milestone, and one pre-seed financing event. The company’s founding date is Jan 1, 2019, while Peter Schlecht’s listed CEO and founder role began in July 2018. On Oct 1, 2021, Braingrade raised $1 million in a pre-seed round. The employee-size classification is 11–50, while one current position and one named leader are identified, so the band should be treated as an estimate rather than a detailed headcount. As of Oct 8, 2026, the long gap since the recorded financing makes the next verifiable inflection points—such as clinical validation, regulatory progress, or a product launch—important to assessing whether the concept has advanced.